Drugs.com Clinical Trial ResultsOriginal article
Marengo Therapeutics Receives Second U.S. FDA Fast Track Designation for Invikafusp Alfa, Expanding to a Tissue-Agnostic Indication Across Tumor Mutational Burden-High Solid Tumors That Progress After Prior Therapy, Including Checkpoint Inhibition
RegulatoryInvikafusp AlfaPositive
AI Analysis
Summary
Marengo Therapeutics received a second FDA Fast Track Designation for invikafusp alfa. The designation covers a tissue-agnostic indication in TMB-high solid tumors that have progressed after prior therapy, including checkpoint inhibition.
Outcome Details
FDA granted a second Fast Track Designation for invikafusp alfa, expanding to a tissue-agnostic indication in TMB-H solid tumors progressing after prior therapy including checkpoint inhibitors
Importance:6/10
Sentiment:
0.60
Fast Trackoncologyimmunotherapytissue-agnosticTMB-Hcheckpoint inhibitor resistanceprivate company
Read the original article
Published by Drugs.com Clinical Trial Results on October 15, 2026 2:10 AM